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meeting was held to analyse to what extent skin sensitisation safety assessments for cosmetic ingre-
dients can be made in the absence of animal data. In order to propose guiding principles for the
application and further development of non-animal safety assessment strategies it was evaluated
how and when non-animal test methods, predictions based on physico-chemical properties (including
in silico tools), threshold concepts and weight-of-evidence based hazard characterisation could be
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area.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction hypothesis being that integration of data from a ‘toolbox’ of non-A standard requirement within the safety assessment of cosmetic
ingredients is to characterise their potential to induce skin sensitisat-
ion under product use conditions that may lead to allergic contact
dermatitis (ACD) in humans. Despite extensive efforts to develop
alternative methods, the sensitising potential of an ingredient cur-
rently needs to be identiﬁed on the basis of animal studies in many
cases, i.e., the murine local lymph node assay (LLNA, OECD (organi-
sation for economic co-operation and development) TG 429)
(Basketter et al., 2007; OECD, 2010) and Guinea pig assays (OECD
TG 406) (OECD, 1992), namely the Maximisation Test (Magnusson
and Kligman, 1969) and the Buehler test (Buehler, 1965).
The LLNA is based on quantiﬁcation of cell proliferation in the
draining auricular lymph nodes after repeated topical applications
of the chemical. By testing multiple concentrations, the assay not
only identiﬁes potential skin sensitisers, but also evaluates their
sensitising potency. Guinea pig tests are based on a visual scoring
of skin reactions after topical application (Buehler test) or intrader-
mal and topical application (Maximisation test) of the chemical at
a dose which induces modest irritation. Approximately three
weeks later the potential of a chemical to elicit an immune re-
sponse is analysed by virtue of a challenge exposure.
Immunologically, skin sensitisation can be described as a de-
layed-type hypersensitivity reaction induced by low molecular
weight reactive chemicals (haptens). It comprises two phases,
induction and elicitation (Karlberg et al., 2008). Fig. 1 schemati-
cally depicts the corresponding steps (1–7) as described in the fol-
lowing: as a ﬁrst step in the induction phase the (possibly oxidised)
chemical must penetrate the skin (steps 1 and 2) to chemically re-
act with endogenous proteins (step 5). Some chemicals require
activation through enzymatic (pro-haptens, step 4) or oxidative
(pre-haptens, step 1) processes in order to become haptens capable
of binding to skin proteins (step 5). The ﬁrst cells to be exposed to
sensitisers are epidermal keratinocytes, which respond to chemical
stress with a cocktail of proinﬂammatory cytokines (step 3) (Cor-
sini et al., 2009). Activated by these mediators as well as in some
cases by direct hapten contact, epidermal Langerhans cells (LC)
and immature dendritic cells (DC) take up and process haptenated
proteins. In parallel they mature into highly effective antigen pre-
senting cells (APC) (Toebak et al., 2009). This maturation includes
the secretion of mediators like IL-8, as well as the expression of
surface markers such as CD86, CD54, or chemokine receptors (step
6) (Kroeze et al., 2009). The latter facilitate the migration of LC out
of the epidermis and guide them to the nearest (local) lymph node
where they present haptenated protein fragments (antigens) to T
cells (step 7) (Ortmann et al., 1992). This step is the link between
the innate and the adaptive immune systems, i.e., recognition of
the antigen by speciﬁc T cell receptors and subsequent speciﬁc T
cell activation. The activated (effector) T cells home to the skin
where upon repeated contact with the same allergen (elicitation
phase) they orchestrate an inﬂammatory response that can lead
to dermal injury. Hence, they are representing the immunological
‘‘memory’’ responsible for the speciﬁcity of the ACD (Martin and
Weltzien, 1994).
COLIPA’s skin sensitisation research programme aims to further
reﬁne our fundamental understanding of how each of these key
pathways contribute to the induction of skin sensitisation and de-
velop in vitro test methods that can predict the effect of a novel
chemical on each of these key pathways (Aeby et al., 2010) theanimal test methods, each developed to model a different key
pathway in vitro, will allow the precise characterisation of a chem-
ical regarding its skin sensitising potency. Which (set) of these
tools will turn out to provide an appropriate prediction is not
yet determined and is under investigation. On May 26–27, 2010
COLIPA organised an expert workshop to propose how in vitro test
methods and combinations thereof may be applied to risk assess-
ment decision-making, in combination with other non-animal risk
assessment elements.
2. Review of existing tools for evaluation of skin sensitisation
risk assessment without animals
Risk assessment of cosmetic ingredients is not a standardised
procedure, but a case-by-case consideration using best science.
Usually a stepwise approach is employed, utilising the entire scope
of information available to reach science-based decisions in a
weight-of-evidence (WoE) assessment. WoE is considered as the
basic principle to avoid unnecessary animal testing, since all rele-
vant existing information is thoroughly evaluated before any new
testing is undertaken, and it is iteratively applied in each step of
the assessment. An expert assessment of the relevance, i.e., scien-
tiﬁc validity or suitability of the purpose of a method or approach
needs to be performed to decide how to weight individual pieces of
information. New testing may be required when the existing infor-
mation is not adequate to support the safety of an ingredient or
when safety issues arise. In general, information can be qualitative
(used for hazard identiﬁcation) and/or quantitative (used for haz-
ard characterisation and risk assessment).
WoE is broadly accepted by legislation and safety assessors as a
basic principle in risk assessment and is explicitly mentioned in
European chemicals and cosmetics legislation, e.g., in the recast
of the European Cosmetics Directive (EU, 2009), REACH (EU,
2006), and the regulation on classiﬁcation, labelling and packaging
(‘‘CLP’’) of substances and mixtures (EU, 2008).
Elements that are available for skin sensitisation risk assess-
ment to gain information that can be used within WoE-based
safety assessment include:
(1) Prediction based on physico-chemical properties (without
experimental testing; expert judgment/in silico): presence
or absence of structural alerts ((quantitative) structure
activity relationships = (Q)SAR), indications for chemical
reactivity with nucleophiles, mechanistic assignment to
reactivity domains including computer-based searches for
structural and functional similarities in data bases such as
DEREK, TIMES, MULTICASE, OECD Toolbox, ToxTree etc.
(2) Read-across based on similar chemicals with available
experimental data: this is usually done by making use of
WoE expert judgement, potentially assisted by in silico tools
such as OECD toolbox, Toxtree etc.
(3) In vitro methods: includes binding capacity towards pro-
teins; responses of human cell types, i.e., primary keratino-
cytes (KC), dendritic cells (DC), and T cells or relevant
immortalised cell lines in terms of bio-markers, cytokine
secretion or gene expression (gene signature).
(4) Historical data: (i)animal studies reliably reporting on skin
sensitisation effects. (ii) human experience with exposure
to substances and preparations regarding cutaneous
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Fig. 1. Key events in skin sensitisation. Schematic representation of processes involved in the induction and elicitation phases of skin sensitisation by allergenic chemicals.
KC: keratinocyte, DC: dendritic cell, StrC: stratum corneum, T: T cell, LLNA: local lymphnode assay, GP: guinea pig, HRIPT: human repeat insult patch test.
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tal human studies with volunteers (e.g., human repeated
insult patch test, HRIPT).
(5) Exposure estimates: standard skin exposure scenarios as
based on guidance of the EU commission Scientiﬁc Commit-
tee for Consumer Safety (SCCS) and/or information on der-
mal bioavailability
(6) Risk assessment methods: quantitative risk assessment
(QRA) for skin sensitisation for which WoE is considered a
basic element, and threshold concepts.
2.1. Prediction based on physico-chemical properties
As the majority of organic skin sensitisers elicit their effect via
covalent bond formation with skin proteins, these reactions can
be described in terms of nucleophilic–electrophilic reaction chem-
istry. The assessment of a molecular structure with regard to its
potential reactivity can be based on expert judgment, in silico tools
and in chemico reactivity determinations. This provides a frame-
work and builds the basis for structure–activity relationship ap-
proaches (SARs) intended to identify chemicals that may interact
with biological systems and have a potential to cause skin
sensitisation.
In order to predict toxicity from structure, it is beneﬁcial to
establish initially whether a compound is electrophilic in nature
and secondly the type of electrophile, especially if this can be asso-
ciated with a speciﬁc mechanism of action. Skin sensitisers can of-
ten be grouped into several reaction mechanistic domains, the
major ones of which are Michael acceptor, Schiff base, SN2, SNAr,
acyl transfer agents, or non reactive and non-pro reactive agents
(Fig. 2). Recent publications summarised the chemistry of these
reaction mechanistic domains (Aptula and Roberts, 2006) and
showed how this concept can be successfully applied to classify
and chemically rationalise published skin sensitisation data sets
(Roberts et al., 2007a, b) (Table 1).
Inclusion of quantitative considerations leads to quantitative
structure–activity relationship approaches (QSARs) able to approx-
imate a chemical’s relative sensitising potency. An overview of
published reactivity-based QSAR models is provided in Table 2.
More recent QSAR models (Roberts et al., 2011, 2006; Robertsand Natsch, 2009) have been evaluated against OECD guidelines
(OECD Quantitative Structure–Activity Relationships Project)
(OECD) and were shown to meet the OECD principles for (Q)SAR
validation. Each one covers a diverse range of structures within a
single reaction mechanistic domain. Earlier QSARs were usually re-
stricted to sets of structurally similar (congeneric series) of com-
pounds. Relative alkylation index (RAI)-based QSARs (Franot
et al., 1994; Roberts et al., 2007a, 1983; Roberts and Basketter,
2000, 1997; Roberts and Williams, 1982) use a composite reactiv-
ity + hydrophobicity parameter, calculated from reaction rate con-
stants and partition coefﬁcients. Those which are RAI-based are
hybrid dose–response/QSARs, in which the biological response
(stimulation index, erythema score etc.) is correlated with a com-
bination of dose/reactivity/hydrophobicity.
2.1.1. In chemico reactivity determination
The general concept that the rate determining step in the skin
sensitisation process is likely to be the reaction of the sensitiser
with skin nucleophiles has led to initiatives to develop methods
and to generate data on the reactivity of chemicals towards model
nucleophiles representing peptide and protein nucleophiles in the
skin. These methods focus on the qualitative and quantitative mea-
surement of reactivity.
Generally, empirical measures of the reactivity of chemicals
with model nucleophiles such as thiol can be used to simulate
the relative rates at which a reactive chemical is likely to bind to
nucleophiles in cellular targets (Gerberick et al., 2008). To empha-
sise the nature of the reaction, it has been termed it in chemico
reactivity (based only on organic chemistry). With this approach
the toxicity (e.g., skin sensitisation) of a new chemical were esti-
mated from measured chemical data for certain subsets of chemi-
cals (Schultz et al., 2009).
Practically, the activity of an electrophile can be quantiﬁed in
terms of the rate constant k, or its logarithm log k, for its reaction
with a nucleophile. They should be determined for a range of elec-
trophiles under the same conditions (same nucleophile, solvent,
temperature). Rate constants (absolute or relative) or their loga-
rithms are often used in physical organic chemistry to express reac-
tivity quantitatively. There are several approaches for determining
rate constants. They are listed in order of decreasing accuracy.
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quinones and ortho quinones, often formed by oxidation of para and ortho di-
hydroxy aromatics acting as pro-Michael acceptors. X can also be a
heterocyclic group such as 2-pyridino or 4-pyridino.
Identification characteristics. X = halogen or pseudohalogen, Y's are electron 
withdrawing groups (at least two) such as -NO2, -CN, -CHO, -CF3, -SOMe,
-SO2Me, ring fused nitrogen...One halogen is too weak to act as an X, but
several halogens together can activate.
Identification characteristics. X = halogen or other leaving group, e.g.
OSO2(R or Ar), OSO2O(R or Ar) bonded to primary alkyl, benzylic, or allylic 
carbon. OR and NHR or NR2 do not usually act as leaving groups, but can do
so if part of a strained 3-membered ring (e.g. epoxides, ethylenimine and
substituted derivatives).
Identification characteristics. X = halogen, or other group (e.g. -OC6H5)
such that XH is acidic enough for X- to act as a good leaving group. Includes
anhydrides, cyclic or non-cyclic. X = -Oalkyl does not qualify, except when
part of a strained lactone ring, e.g. β-propiolactone (but not γ-butyrolactone). 
Analogous reactions can occur with attack at sulfonyl S, phosforyl P
and thioacyl C.
Identification characteristics. Reactive carbonyl compounds such as aliphatic 
aldehydes, some α,β- and α,γ-diketones, α-ketoesters. Not simple
monoketones and aromatic aldehydes. Other hetero-unsaturated systems can
behave analogously, e.g. C-nitroso compounds, thiocarbonyl compounds
(C=S), cyanates and isocyanates, thiocyanates and isothiocyanates.
Fig. 2. Reaction mechanistic applicability domains (Aptula and Roberts, 2006).
Table 1
Assignment of LLNA-typed chemicals to different reactivity domains. A total of 344 chemicals, which had previously been classiﬁed by LLNA into sensitisers and non-sensitisers,
were assigned to different reactivity domains deﬁned in Fig. 2 (Roberts et al., 2007a, b).
Chemical domain LLNA data distribution
Total Sensitiser Non-sensitiser Sensitisers [% of total]
Michael acceptors 97 89 8 92
SNAr electrophiles 3 3 0 100
SN2 electrophiles 61 49 12 80
Schiff base formers 56 46 10 82
Acylating agents 30 28 2 93
Non-reactive 97 38 59 39
C. Goebel et al. / Regulatory Toxicology and Pharmacology 63 (2012) 40–52 432.1.1.1. Full kinetics. In a typical kinetics experiment the extent of
reaction, either in terms of depletion of one of the reactants or in
terms of formation of a reaction product, is measured at severalrecorded time intervals, and from these the rate constant k is cal-
culated (for more details see (Chipinda et al., 2010; Roberts et al.,
2008; Roberts and Natsch, 2009).
Table 2
Published reactivity-based QSAR models.
Ref. Reactivity parameter Other parameters Applicability domain Test system RAIa-based
Roberts et al. (2006) Substituent constants Hydrophobicity Schiff base LLNA No
Roberts and Natsch (2009) Peptide kinetics (logk) None Michael acceptors LLNA No
Roberts et al. (2011) Substituent constants None SNAr LLNA No
Roberts et al. (2007a) BuNH2b kinetics/LFERc Hydrophobicity H-polar SN2 LLNA Yes
Franot et al. (1994) BuNH2 kinetics Hydrophobicity H-polar SN2 (single set of structural congeners) GPd (MSIATe) Yes
Roberts and Basketter (2000) BuNH2 kinetics Hydrophobicity H-polar SN2 (sulphonate esters) LLNA Yes
Roberts and Basketter (1997) BuNH2 kinetics Hydrophobicity H-polar SN2 (sulphonate esters) GP (MSIAT) Yes
Roberts et al. (1983) BuNH2 kinetics Hydrophobicity H-polar SN2 (single set of structural congeners) GP (MSIAT) Yes
Roberts and Williams (1982) BuNH2 kinetics Hydrophobicity Sultones (SN2 and Michael acceptors separately) GP (SIAT) Yes
a RAI – relative alkylation index.
b BuNH2 – butylamine.
c LFER – linear free energy relationship.
d GP – guinea pig.
e MSIAT – modiﬁed single injection adjuvant test.
44 C. Goebel et al. / Regulatory Toxicology and Pharmacology 63 (2012) 40–522.1.1.2. Concentration giving 50% reaction in a ﬁxed time
(RC50). Methods based on this approach have been developed,
which is designed to generate a quantitative reactivity database
which can be used for in chemico modelling for a variety of toxico-
logical end points, including skin sensitisation. A concentration re-
sponse method is used to quantify reactivity in aqueous solution to
the model nucleophile glutathione (GSH) in terms of the RC50 va-
lue, with RC50 being the concentration of electrophile that de-
pletes the thiol group of GSH by 50% (Roberts et al., 2008;
Schultz et al., 2005).
2.1.1.3. Extent of reaction after a ﬁxed time. Another method is to
determine the extent of reaction (which can be expressed as%
depletion, DP of one of the reactants) after a ﬁxed time. Although
not as accurate as a kinetics experiment, since only two data points
are used, rough estimates for second order rate constants can be
estimated (Roberts et al., 2008). This method has been used to de-
velop a peptide depletion assay approach, namely the Direct Pro-
tein Reactivity Assay (DPRA) (Gerberick et al., 2007, 2004) which
is described in detail below (see Section 2.3). Especially since this
assay is already well advanced (i.e., under prevalidation) it will
be used in the following (see Section 2.7) to represent chemical
reactivity determination. In a similar approach, quantitative LC-
MS/MS technology was used to determine whether a chemical is
reactive towards different protein nucleophiles by observing both
the disappearance of target peptide and formation of adduct(s)
(Aleksik et al., 2009). Furthermore, an assay based on a heptapep-
tide and quantitative LC-MS to measure peptide depletion and ad-
duct formation was introduced (Natsch and Gfeller, 2008). This
modiﬁcation of the original HPLC assay has the advantage that also
quantiﬁcation of peptide oxidation (dimerisation) can be
measured.
2.1.2. In silico tools
The utility of two commonly used in silico SAR tools, namely the
database-assisted expert system DEREK (Judson, 2002; Rodford
et al., 2003) and the OECD Toolbox (OECD) were discussed with re-
gard to their predictive capacity for skin sensitisation. It could be
shown that the predictive capacity of these models is largely inﬂu-
enced by the data sources and prediction systems used. These tools
are not designed as a stand alone replacement, but may be useful
within a structured decision support system as part of a safety
assessment strategy.
Data was shared during the workshop from a company study
that was conducted in 2009, which compared the predictive capac-
ity of the DEREK (version 10) and the OECD Toolbox (version 1), by
concordance analysis and WoE approach (Quayson et al., 2010).
The output of each model (see Fig. 3) was compared to LLNA resultsfor 249 chemicals from an in-house database representing a broad
spectrum of chemical classes known to cause skin sensitisation in
animals and/or man, including acrylates, ketones and diketones,
aldehydes, aromatic amines, sulphonates, sulphates and quinines.
The overall concordance with the LLNA was low in both systems,
although DEREK performed slightly better than the OECD Toolbox
(63% vs. 53% overall concordance). Both computer programmes
gave many false positive predictions, which may, as indicated, be
partly due the limited dataset that was used to train the pro-
grammes. Predictions for some chemical classes performed sub-
stantially better than the systems in general, particularly for
haloalkanes, with correct predictions of up to ca 70%. Negative pre-
dictivity reached up to 70%, indicating that (Q)SAR may be used as
part of a combination of approaches to obtain information for pri-
ority setting. Importantly since these analyses were conducted in
2009, data from these 249 chemicals, in addition data from other
sources and systems, were uploaded to DEREK and made available
in version 12 to add to the existing dataset. Version 2 of the OECD
Toolbox has also been made available recently and might be fur-
ther assessed. The OECD Toolbox is referred to as SAR tool and
can be used to identify structural alerts for contact hypersensitiv-
ity. However, predictions based on structural alerts alone show a
poor overall accuracy and use only one of the functionalities cur-
rently implemented in the OECD Toolbox. Therefore, a more prom-
ising evaluation strategy would be to build a category of related
molecules around the target chemical by sequentially applying
the mode of action proﬁlers, structural classiﬁcation rules, and ﬁ-
nally the bioavailability prediction functionality.
The EU JRC commissioned the development of the open source
computer programme ‘‘Toxtree’’ (2010, http://toxtree.source-
forge.net/), which is able to estimate toxic hazard by applying
structural rules. The skin sensitisation alerts were those developed
by Aptula and Roberts (2006) and subsequently encoded as
SMARTS patterns by Enoch et al. (2008).2.1.2.1. Recommendations for further research. To support expert
judgement, in silico approaches are considered to have a potential
value when used as part of a WoE strategy for the assessment of
skin sensitisation.
Mechanistic chemistry classiﬁcation and assignment to mecha-
nistic domains is already possible for many chemicals. This can be
done through inspection of the structure and can be supported and
reﬁned by reactivity determinations. Based on the current knowl-
edge, quantitative measurement of reactivity is considered a very
promising approach helping to link protein reactivity to skin sensi-
tisation potency. However, the available approaches are mainly
based on reactivity towards thiol groups and therefore have limita-
tions in capturing all reactivity domains. Therefore, further
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Fig. 3. Comparison of the performance of DEREK and the OECD toolbox with LLNA data in predicting skin sensitisation.
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more difﬁcult to assess by e.g., amine-based, non-water assays. An-
other limitation is that the assays detect only directly active elec-
trophiles, while a number of skin allergens requires activation
(either by abiotic oxidation or metabolic activation) to form an
electrophilic reactive molecule. Therefore, future in chemico assays
should target to also capture not directly active chemicals. Promis-
ing progress has already been made in this area by integrating an
activation step into the Direct Protein Reactivity Assay (Gerberick
et al., 2009; Troutman et al., 2010).
The accuracy of the assessment (both negative and positive pre-
dictivity) may be approved by additional considerations of phys-
ico-chemical information such as molecular weight, LogPOW,
solubility, predicted maximum ﬂux/dermal penetration. One
example is high molecular weight chemicals such as polymers
which lack structural alerts and fail to penetrate the stratum cor-
neum. Exposure through the dermal route may thus be considered
as negligible and will not require further testing, as long as impu-
rities or unconverted monomers have been evaluated and are not
of concern. For other molecular structures these properties must
be assessed on an individual basis possibly requiring more detailed
investigation.
The principle of uploading available data to the DEREK and
OECD toolbox databases should be actively supported. By extend-
ing these databases the capacity for predicting skin sensitising
properties of cosmetic ingredients may be improved.2.2. Read-across based on similar chemicals with available
experimental data
2.2.1. The OECD toolbox
One of the currently developed and ofﬁcially promoted tools for
read-across considerations based on the chemical structure or do-
main is the OECD Toolbox that has already been mentioned above.
In some cases, sufﬁcient read-across data on structurally similar
materials might be available and provide information on the skin
sensitising potential. The ﬁndings from the analysis described in
the previous (Section 2.1), reported an overall concordance of the
OECD Toolbox with the LLNA of 53% based on 249 chemicals,
demonstrating that the direct correlation to LLNA data is stillinsufﬁcient. There were many false positive predictions. Negative
predictivity was more accurate (70%), which still underlines the
utility of the toolbox as part of a package of approaches for priority
setting.
Using the OECD Toolbox with the data gap ﬁlling function did
improve the overall concordance of the predictions with the LLNA
to 77%. Positive predictivity of both, DEREK and the OECD Toolbox,
could be improved by considering physico-chemical properties
used to predict dermal absorption, and bacterial mutagenicity data
as surrogate for information on reactivity (Quayson et al., in press).
Considering this type of information may generally improve
the conﬁdence in the output of (Q)SAR and/or read-across
assessments.2.2.2. Read-across and weight-of-evidence (WoE) in regulatory risk
assessment. Examples from public databases
A meta-analysis of published literature and databases was
performed to identify examples how read-across is applied in the
context of regulatory decision-making. As explained above, read-
across and WoE are considered basic principles in current risk
assessment. However, the application needs thorough justiﬁcation
and is often limited, especially for highly complex toxicological ef-
fects. In general, data from SCCS opinions, CIR (cosmetic ingredient
review) reports, OECD HPV (high production volume) dossiers,
HERA (human and environmental risk assessment) risk assess-
ments, and PubMed were used. After a thorough review of that
literature, it turned out that the identiﬁed examples can mainly
be grouped into several major categories which are listed in Table
3 together with some examples identiﬁed for each category.
It was also identiﬁed that read-across is usually combined with
WoE. An explicit mention of the use of these principles and a clear
justiﬁcation, however, was found only in a limited number of
examples. Assessments related almost exclusively to individual
substances rather than categories. Major ﬁelds of application were
(a) hazard identiﬁcation to derive appropriate classiﬁcation, or (b)
risk assessment to deﬁne concentration levels and/or thresholds
for safe use. Extra- or interpolation in case of data-poor substances
was rarely done. In those cases where a category justiﬁcation was
made, a signiﬁcant variation of quality and level of detail could be
observed. With regard to products, assessment is mostly based on
Table 3
Read-across/WoE from public databases.
Chemical group characteristics Examples Source
1 Salts where the respective counter-cations or anions are ‘‘neutral’’; salts and
their respective acids
Nickel salts OECD
Thioglycolic acid and ammonium or sodium salts OECD
Benzoic acid SCCP
2 Close homologues with varying carbon chain length Anionic surfactants (alkyl sulphates, alkane sulphonates, a-oleﬁne
sulphonates)
OECD
a-Oleﬁnes OECD
Alkylamidopropyl betaines (amphoteric surfactants, carboxylic structure,
varying chain length)
OECD
Linear alkylbenzene sulphonates HERA
3 Ethers from the same alcohol, or alkoxylates from different alcohols Ceteareth-n, various polyoxyethylene ethers of cetearyl/stearyl/
cetylaclohol
CIR
Ceteth-n, various PEG ethers of cetyl alcohol CIR
Alcohol ethoxylates HERA
Alcohol ethoxysulphates HERA
Propylene glycol ethers (Vink et al., 2010) PubMed
4 Related esters Ester quats HERA
2 Alkyl ester quarternary ammonium cpds. (Jowsey et al., 2007) PubMed
Glyceryl myristate and related esters CIR
PEGs sorbitan fatty acid esters CIR
5 Similar polymers Polyacrylic acid homopolymers, poly-(acrylic/maleic) acid copolymers
and their sodium salts
HERA
Acrylates, polyacrylates, various acrylate copolymers CIR
Rosin-based substances (Illing et al., 2009) PubMed
6 Plant extracts Storax (Liquidambar orientalis balsam extract + oil; Liquidmbar styraciﬂua
balsam extract + oil)
SCCP
Opoponax (Commiphora erythrea glabrescens gum extract + oil) SCCP
Table 4
Alternative assays available within COLIPA and other organisations.
Method Developed by Assay type Reference Mirroring step in
Fig. 1
1. Toxicokinetic J. Kasting, Uni of
Cincinnati, USA
In silico Wang et al. (2006) 2
2. DPRA P & G In chemico Gerberick et al. (2004, 2007) 5
3. MUSST L’Oreal DC in vitro Ade et al. (2006) 6
4. h-CLAT KAO&Shiseido DC in vitro Ashikaga et al. (2006), Sakaguchi et al. (2006) 6
5. NCTC IL-18 test Sens-it-iv KC in vitro Corsini et al. (2009) 3
6. Tiered approach Sens-it-iv KC and epidermal equivalent Corsini et al. (2009), Spiekstra et al. (2009) 2, 3
7. AREc32 CXR Biosciences AREc32 cells in vitro reporter gene
activity
Natsch and Emter (2008) 3, 6
8. MUTZ-3 Gene
signature
Sens-it-iv DC in vitro gene expression Johansson et al. (2011) 6
9. Peptide reactivity Unilever In chemico Aleksik et al. (2009) 5
10. DPRA next
generation
P & G Univ. Strasbourg In chemico Gerberick et al. (2009) 1, 4, 5
11. KeratinoSens Givaudan KC in vitro, reporter gene activation Emter et al. (2010) 3, 6
12. VITOSens™ CARDAM-VITO DC in vitro Gene expression Hooyberghs et al. (2008) 6
13. PBMDC Beiersdorf moDC in vitro Reuter et al. (2011) 6
14. SenCeeTox™ CeeTox GSH depletion & KC in vitro gene
expression
McKim et al. (2010) 3, 5
15. Multi parameter
biosensor
Univ. of Toledo, Ohio, USA DC in vitro, reporter gene activation Mizumoto et al. (2002, 2003, 2005) 3, 6
16. DC migration Imperial College London DC in vitro, reporter gene activation Pease and Williams (2006) 6
17. T cell proliferation Univ. Freiburg PBMC in vitro Martin et al. (2010), Kotturi et al. (2008), Moon
et al. (2007)
7
18. T cell proliferation Univ. Lyon PBMC in vitro Vocanson et al. (2006) 7
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ilar products could be used. In some cases theWoE approach is also
used for the quality evaluation of speciﬁc test data.
As a general recommendation, a sound rationale for the ap-
proach in each individual case should be provided to demonstrate
the scientiﬁc validity. The rationale needs to take into consider-
ation the applicability for the class of chemical under investigation.
This can be done by providing in vitro data demonstrating that the
chemistry-based prediction is supported by real data for direct
comparison to chemicals of the identical applicability domain.2.3. In vitro methods
The non-animal test methods currently under development or
evaluation (within the COLIPA research programme or by other
organisations (Table 4) aim to replace the need for new animal test
data through predicting how cosmetic ingredients will affect the
various chemical or biological pathways identiﬁed as relevant to
the induction of skin sensitisation in humans so far. At present, none
of these in vitro testmethods has been accepted by national or inter-
national regulatory authorities as a partial or full replacement for
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bers, the following three assays are being evaluated for inclusion in
testing strategies for hazard and risk assessment in several
companies:
 The direct peptide reactivity assay (DPRA) discriminates sensi-
tisers (S) from non-sensitisers (NS) on the basis of their chemi-
cal reactivity towards two synthetic peptides (containing either
a single cysteine or lysine as a reaction target) and by measur-
ing their depletion using High Performance Liquid Chromatog-
raphy. As an improvement to this assay an oxidation step has
been included (No. 10 in Table 4) using hydrogen peroxide in
the presence or absence of horseradish peroxidase to oxidise
the chemical under investigation to enable detection of pre-
and pro-haptens (Gerberick et al., 2007).
 The myeloid U937 skin sensitisation test (MUSST) uses ﬂow
cytometry to determine induction of the activation marker
CD86 on the DC line U937 for S/NS discrimination (Ade et al.,
2006; Rousset et al., 2002).
 The human cell line activation test (h-CLAT) employs the DC
line THP-1 and bases S/NS decision on CD86 plus CD54 induc-
tion (Ashikaga et al., 2006; Sakaguchi et al., 2006).
DPRA, MUSST and h-CLAT are part of an ECVAM Phase III pre-
validation study (Hartung et al., 2004) and some of the other tests,
such as the tired approach (using keratinocytes and epidermal
equivalents; see No. 6 in Table 4) and the KeratinoSens (using re-
porter gene activation in keratinocytes; see No. 11 in Table 4),
are short of entering pre-validation experiments.2.3.1. Recommendations for further research
The improvement of in vitro assays is considered as a major to-
pic for further development to allow for hazard identiﬁcation and
potency prediction in a future WoE approach. Currently, the DPRA,
h-CLAT and MUSST have been the subject of substantial evaluation
including inter-laboratory assessments and have been accepted by
ECVAM for inclusion in a pre validation study. Assuming a success-
ful outcome, they may soon be included in a hazard identiﬁcation
toolbox. However, to generate potency information, there is cur-
rently only a limited understanding which assays or which combi-
nation thereof may be best suited. Thus, further research is needed
to identify the most promising assays and to increase the under-
standing how in vitro results can be interpreted to provide potency
information to ﬁnally feed into practical decision-making pro-
cesses as applied under QRA approaches.2.4. Historical data
The evaluation of the quality of data and its subsequent use in
the hazard and risk assessment is an important aspect. In general,
information regarding the test substance, the test report/protocol
is critical and their relevance and reliability should be considered
based upon expert judgement. This also applies to studies pub-
lished in the peer-reviewed literature and justiﬁcation of the
acceptability of these studies might be required. Decisions to in-
clude or reject a study for risk assessment purposes must be made
on case-by-case bases taking into account factors such as the
importance of the study in the context of the risk assessment
e.g., the extent of the deﬁciencies of the existing study versus cur-
rent testing methodologies and the applicability/extent of other
supporting data.
Evaluation of standardised animal studies should follow the
general requirements for the LLNA or the Guinea pig tests as pro-
vided in the respective OECD guidelines and in the ECETOC techni-
cal report on skin sensitisation (ECETOC, 2003).Evaluation of historical human experiencewith exposure to sub-
stances and preparations that report on cutaneous reactions (aller-
gic contact dermatitis, eczema)may come from a variety of sources:
 Consumer experience and comments, possibly followed up by
professionals (e.g., diagnostic patch tests, bronchial provocation
tests, skin prick tests and measurements of speciﬁc IgE serum
levels).
 Diagnostic clinical studies.
 Records of workers’ experience, accidents, and exposure studies
including medical surveillance.
 Case reports in the general scientiﬁc and medical literature.
 Consumer tests (monitoring by questionnaire and/or medical
surveillance).
For the above listed data frequency and severity of the reported
effects needs to be evaluated on a case by case basis and requires
expert judgement.
More precise information can be obtained if human experimen-
tal data are available. For skin sensitisation there are volunteer
studies such as the HRIPT and the human maximisation test
(HMT). Respective outlines of these clinical test protocols and for
the necessary ethical considerations are available in the ECETOC
monograph No. 32 (ECETOC, 2002). The robustness of a given pro-
tocol depends among others on the number of dose groups, the
application frequency, the amount applied and the skin site used
for application. Depending on the quality of the data, potency
information can be obtained.
2.5. Exposure assessment
The objective of exposure assessment is an estimate of the dose/
concentration of the substance to which humans may be exposed,
considering duration and frequency of their exposure. Since cos-
metic products cover a wide range of product types, various expo-
sure scenarios exist. Regarding skin sensitisation, every speciﬁc
exposure scenario will be linked to a certain amount of substance
that may be applied to the skin surface and might have access to
the living epidermis through dermal absorption.
Generally, in use exposure levels can only be obtained on a
case-by-case basis taking into consideration at least the following
factors (SCCP, 2006):
- class of cosmetic product(s) in which the ingredient may be
used,
- method of application,
- concentration of the ingredient in the ﬁnished cosmetic
product,
- quantity of product used at each application,
- frequency of application,
- total area of skin contact,
- site of skin contact,
- duration of contact (e.g., rinse-off products),
- foreseeable misuse which may increase exposure,
- consumer target group (e.g., children, people with ‘‘sensitive
skin’’).
Furthermore, usage of cosmetic products may depend on habits
and practices of usage including factors such as age group, seasonal
variations, local habits, fashion, trends, disposable income, and
product innovation. Typical exposure scenarios for cosmetic prod-
ucts are provided in the SCCP’s ‘‘Notes of guidance’’ (SCCP, 2006).
For a skin sensitisation exposure assessment the skin surface
area exposed with the cosmetic product (dose/unit area) contain-
ing the ingredient under study, has to be known, as well as the fre-
quency of application of the product.
Identify sensitisation potential, e.g. LLNA 
Define no expected skin sensitisation 
induction level (NESIL) 
Apply sensitisation assessment factors 
(SAFs): 
•inter-individual variability (x 10) 
•vehicle/product matrix effects (x 1 – x 10) 
•use considerations (x 1 – x 10) 
Acceptable exposure level (AEL)
Compare AEL with consumer exposure 
level (CEL) 
Market product 
and monitor 
consumer and 
clinical feedback 
?
Fig. 4. Quantitative risk assessment (QRA). Simpliﬁed ﬂow diagram for the conduct
of a quantitative risk assessment (QRA) using animal-derived skin sensitisation
potency data (LLNA = local lymph node assay in mice); modiﬁed from (Basketter
et al., 2008).
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metics can be obtained from dermal absorption studies following
the requirements of the corresponding OECD guidelines 427 and
428 (OECD, 2004a,b).
2.6. Risk assessment approaches
2.6.1. Quantitative risk assessment
The risk of induction of skin allergy to a particular ingredient in a
product under speciﬁc exposure conditions can be determined
using the quantitative risk assessment approach (QRA; see Fig. 4).
This is a predictivemodel based upon evaluation of two parameters.
Firstly, the identiﬁcation of the intrinsic sensitisation potency of
an ingredient (deﬁned in a WoE approach) is undertaken to obtain
a no effect level (No Expected Sensitisation Induction Level, NESIL).
To this, appropriate Sensitisation Assessment Factors (SAF) have to
be applied in order to provide an estimate of acceptable human
exposure levels below which the adverse effect, i.e., the induction
of skin sensitisation, should not occur in a population of consumers
using this product.
The second component of the QRA is the quantiﬁcation of the
actual consumer exposure (Consumer Exposure Level, CEL, ex-
pressed as dose per unit area) to the ingredient during use. Only
both components together provide a scientiﬁcally relevant quanti-
ﬁcation of the risk of skin sensitisation associated with product
usage. Comprehensive details of this approach have been delin-
eated in a series of publications (e.g., Felter et al., 2002, 2003).
The major elements of the QRA concepts will be brieﬂy described
as follows:
2.6.1.1. Determination of the NESIL. The WoE NESIL is a derived
threshold taking into account all relevant skin sensitisation data,
mainly from LLNA and if available from HRIPT data and/or Guinea
pig studies used as supportive evidence (Api and Vey, 2008;
Basketter et al., 2000, 2005; Gerberick et al., 2001; Griem et al.,
2003; Schneider and Akkan, 2004). The NESIL is always deﬁned
as a dose per unit area (e.g., lg/cm2).
Based on potency values obtained in the LLNA (EC3, effective
concentration of the test substance required to produce a threefold
increase in the stimulation index compared to vehicle-treated con-
trols), sensitisers are grouped into four categories, each covering
one order of magnitude (i.e., extreme (EC3 <0.1%), strong (EC3
P0.1–<1%), moderate (EC3 P1–<10%) and weak (EC3 P10–
6100%)) (ECETOC, 2003; Kimber et al., 2003; Loveless et al.,
2010). In cases where LLNA data exist for structural analogues
within the same chemical class, a surrogate NESIL (based upon
lowest EC3 in potency class) might be assigned based upon the
above for use in a QRA. This procedure includes the conservative
assumption to use the lowest EC3 value of the category assigned.
2.6.1.2. Derivation of an SAF. In dermal sensitisation risk assess-
ment in general, it is necessary to extrapolate from the deﬁned
and controlled experimental conditions within the hazard charac-
terisation tools used to obtain the data for deﬁning the NESIL to the
conditions that exist during consumer exposure to the product.
This is achieved by the application of SAFs, which accounts for
three parameters: (a) inter-individual variability, (b) vehicle/prod-
uct matrix differences and (c) use considerations. The total SAF ap-
plied will be product speciﬁc and in practice could range from 10
(for products not intended to come into contact with skin) to
1000 (for products applied to sensitive areas of the body). The con-
cept and the parameters affecting the SAF are well described in the
literature (reviewed in Felter et al., 2002, 2003).
2.6.1.3. Human exposure. The CEL is a measure of exposure under
intended and foreseeable conditions of use and takes into account,habits and practices, frequency and duration of use and amount of
product used per application.
The two key elements for risk characterisation are the Accept-
able Exposure Level (AEL) and the comparison of the AEL to the
CEL. The AEL is determined by dividing the WoE NESIL by the SAF
and is expressed as dose per unit area. If for a particular ingredient
the relationship is AEL > CEL, it is considered that the proposed
exposure to this ingredient poses negligible risk of induction of skin
sensitisation (see Fig. 4).2.6.2. Threshold concepts
Inspired by the TTC (Threshold of Toxicological Concern) con-
cept for systemic toxicity, originally developed in the food sector
(Rulis, 1986) and accepted in that area for certain applications
e.g., for food ﬂavours, and adaptation of the TTC concept has re-
cently been suggested for skin sensitisation for ingredients used
in cosmetic and personal care products. In general, the TTC concept
deﬁnes chemical exposures below which the general risks of ad-
verse toxicological effects are considered to be negligible (Kroes
et al., 2004).
Two similar TTC concepts for the potential to induce skin sensi-
tisation have been recently suggested based on animal and human
data sets: the Dermal Sensitisation Threshold (DST) (Safford, 2008)
and the Threshold of Sensitisation Concern (TSC) (Keller et al.,
2009). While DST and TSC both address the same human sensiti-
sation threshold expressed in the appropriate dose metric (lg/
cm2), the calculations are based on different data sets: the DST re-
lies on available animal (LLNA) data, the TSC employs a database
with human experience. The two analyses therefore can be consid-
ered as complementary exercises. The combined results indicate
that human data-derived ﬁndings largely support conclusions
drawn from the LLNA data.
In addition to the published data (Safford, 2008), a proposal has
been made to further reﬁne the DST by classifying chemicals
according to their protein binding potential using data of (Aptula
and Roberts, 2006; Safford et al., 2011). In this way a higher thresh-
old value can be assigned to chemicals which are classiﬁed into the
nonreactive domain. Such an analysis of structural alerts could also
be used to derive more differentiated TSC values as indicated by
Keller et al. (2009). Table 5 shows maximum concentrations of
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application of the DST, reﬁned DST and TSC approaches.
2.6.2.1. Recommendations for further research. Identiﬁcation of the
presence/absence and the quality of structural alerts (as indicated
by chemistry prediction) might be used to reﬁne the threshold
determination and lead to a more targeted and accurate applica-
tion of threshold concepts. The same may in the future hold true
for testing information from in vitro methods in a similar manner
as it was suggested for the TTC concept (Cheeseman et al., 1999).
In addition, expanding the underlying datasets which deﬁne the
threshold would further substantiate the applicability domain of
these approaches and possibly lead to a more comprehensive
system.
2.7. Integration of the available tools
The integration of data/information from the available tools is
considered the way forward for future safety assessment, but indi-
vidual tests and combinations thereof are not yet at a ﬁnal stage of
development. To further optimise the approach, generation of
comprehensive databases including the results obtained with a lar-
ger set of chemicals is needed to increase its value for safety
assessment purposes. This is already the case for tools in an ad-
vanced development stage, which in many instances are already
applied for decision-making within industry. For example, compar-
ison of in vivo benchmark data (e.g., LLNA data) with results from
the same chemical analysed in the three in vitro assays currently
under pre-validation (e.g., DPRA, h-CLAT and MUSST) could be fur-
ther expanded by performing in silico predictions and application
of threshold concepts. Table 6 illustrates which mechanistic as-
pects are included in the three in vitro assays currently under
pre-validation compared to in vivo and T-cell assays. Since none
of the in vitro assays (with the DPRA being also representative of
in chemico reactivity prediction) covers all mechanistic aspects of
the in vivo immune response, it needs to be further investigated
which (set of) tools is needed in order to achieve an appropriate
prediction. It should be noted that DPRA/chemical reactivity deter-
mination provides a high correlation with LLNA results (Gerberick
et al., 2008) but does not address known chemical reactivity inde-
pendent mechanisms as e.g., described for metal ions such as nick-
el (Martin et al., 2010).
Gaining and sharing experience of data integration for risk
assessment should allow to identify what data/information will
be most valuable for certain chemicals and exposure scenarios.
The aim will be to create guidelines on how to make use of generic
data types (e.g., peptide reactivity data) rather than speciﬁc test
methods. It may turn out that an appropriate prediction can al-
ready be derived from a quite limited dataset without the necessity
to reﬂect all key mechanistic in vivo processes.Table 5
Examples of the application of threshold concepts (DST and TSC) to suggest maximum us
Product type DSTa derived AEL (lg/cm2)/use conc. (%) Reﬁned D
Rinse-off
Shampood (rinse-off, SAF 100) 1.64/2.1 9/11.7
Conditioner (rinse-off, SAF 100) 1.64/1.6 9/9.3
Leave-ond
Face cream (leave-on, SAF 100) 1.64/0.06 9/0.33
Body lotion (leave-on, SAF 300) 0.55/0.11 3/0.6
Deo/AP (leave-on, SAF 300) 0.55/0.007 3/0.04
a Derived by probabilisitc analysis, gamma distribution, 75 percentile from distributio
b Chemicals classiﬁed in the non-reactive domain (Safford et al., 2011).
c Derived by probabilisitc analysis, skew normal distribution, 95 percentile from distr
d Product exposure estimates were performed according to SCCS Notes of Guidanc
publications cited under.a–c3. Guiding principles for the use and further development of
available tools in the context of skin sensitisation safety
assessment
Based on the thorough analysis of the currently available tools
described in the previous chapter, it was evaluated as to how a pro-
cess to assess the risk to induce skin sensitisation for a new chem-
ical could be structured without new in vivo (LLNA) data. The term
‘guiding principles’ was considered appropriate to express that the
suggested process is a pragmatic starting point to combine the
tools available for a risk assessment in a WoE approach giving
space for further reﬁnement/development.
In addition, there is the need to emphasise that expert knowl-
edge is a key factor to decide if the available data are sufﬁcient
to perform a risk assessment on a case by case basis when follow-
ing the suggested guiding principles or if for the chemical class un-
der review additional information is needed that might not be
obtained with the currently available tools.
As an example, Fig. 5 suggests a process for data combination
and interpretation. It allows in a stepwise manner a consideration
for both hazard classiﬁcation and/or risk assessment or if addi-
tional data would be needed to allow for a decision regarding the
risk of skin sensitisation under use conditions.
An initial need in the safety assessment process is to answer the
question whether a certain ingredient may present a hazard at all
and is usually considered in parallel with the expected exposure
from the product type(s) of interest.
First, an assessment of all relevant existing data including those
from humans and animals should be performed. If sufﬁcient data
are available to identify a material as a non-sensitiser, then this
status can be assigned. If this is not the case, a ﬁrst step in evalu-
ating the safety of a material would be to consider the degree of
human exposure and consider whether it is appropriate to apply
the concept of the TTC.
If not, information on the physico-chemical properties, veriﬁca-
tion of structural alerts, and the mechanism of action may be suf-
ﬁcient to allow for hazard assessment and/or for priority setting.
If there is still insufﬁcient information, data from in vitro assays
could be considered. It should be recognised that data from one or
multiple assays may be required. One criterion for the assay selec-
tion could be its performance during interlaboratory evaluation
(ring trials) and the number of chemicals tested. Currently, these
are the DPRA for information on chemical reactivity and the
h-CLAT and MUSST for dendritic cell responses.
The other initial key consideration apart from the yes/no ques-
tion regarding the hazard is the exposure assessment, as the quan-
tiﬁcation of exposure is a prerequisite for the quantiﬁcation of risk.
For cosmetics, this information can be taken from generally applied
standard data on habits and practices of use (e.g., SCCS, 2010) and
should include information on intensity, frequency and duration ofe levels in cosmetic rinse-off and leave-on products.
STb derived AEL(lg/cm2)/use conc. (%) TSCc derived AEL(lg/cm2)/use conc. (%)
0.9/1.2
0.9/0.93
0.9/0.033
0.3/0.06
0.3/0.004
n (Safford, 2008).
ibution (Keller et al., 2009).
e (SCCS, 2010) and values were modiﬁed accordingly compared to the original
Table 6
Mechanistic skin sensitisation parameters addressed in individual test systems.
Skin
penetration
Skin
metabolism
Chemical
reactivity
Innate immune activation (dendritic cells) Adaptive immune
activation
(T cells)
Contact dermatitis (patch test) + + + + +
LLNA +a +a + + ++
DPRA – –b ++ – –
MUSST – ? + ++ –
h-CLAT – ? + ++ ––
T cell assay – ? + + ++
+ Parameter indirectly assessed.
++ Parameter directly assessed.
? Ability to address parameter unclear.
a May be different to human skin.
b Metabolic activation has been included in next generation of assay (Gerberick et al., 2009).
hazard characterisation
/ potency
hazard identification exposure assessment
chemistry prediction:
(non-testing) 
• phys-chem properties
• structural alerts
• mechanistic domain
threshold concepts
(DST/TSC)
WoE consideration for potency/ 
read across
• based on chemistry predictions
• based on historical data
skin metabolism (pro-haptens) 
and/or
auto-oxidation (pre-haptens)
dermal bioavailability
such as percutaneous
absorption in vitro
potency (W, M, S, E)
„surrogate NESIL“
QRA
information for hazard
classification
expected human exposure
scenario
(standard procedure:  
SCCS guidance)
in vitro assays selected from
toolbox for induction of skin
sensitisation
Fig. 5. Elements for non-animal skin sensitisation safety assessment approaches of cosmetics.
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assessing the dermal bioavailability, i.e., the amount that can reach
the living parts of the epidermis where skin sensitisation is initi-
ated provided the knowledge base for interpretation is sufﬁciently
developed.
In vitro assays, such as the DPRA, h-CLAT and MUSST (Nos. 2, 3
and 4 in Table 4) have been discussed in Section 2.3. Although cur-
rently still under evaluation for the purpose of hazard identiﬁca-
tion, they might be used to support the decision making process
in a WoE risk assessment. There are initial indications that within
certain applicability domains the results can also be used for
obtaining relative potency estimations. In order to test this hypoth-
esis, the in vitro derived potency information should be compared
to the corresponding in vivo data (within their respective applica-
bility domains). If such an approach is considered valid no new
in vivo data might be needed.
Furthermore, possible activation of the chemical through skin
metabolism (pro-hapten) and/or auto oxidation (pre-hapten)
should also be considered during the WoE evaluation. For pre-hap-
tens, the oxidised form is relevant for the induction of skin sensiti-
sation but depending on the exposure conditions might not be
generated during product use.
Already today there can be cases where all above considerations
may justify the assignment of a potency class (i.e., weak, moderate,strong, extreme; for reference see (ECETOC, 2003) and derivation of
a corresponding surrogate NESIL to be ﬁnally used in a QRA as
described in Section 2.5. In most instances however the current
toolbox is not yet sufﬁciently developed to assign a potency class
without animal data.
4. Conclusions
Current hazard and risk assessment of skin sensitisation is com-
monly based on WoE assessments, which in most cases make use
of animal (LLNA) data. Future WoE-based approaches will depend
on the use, optimisation and new development of non-animal tools
and their integration into appropriate assessment/testing strate-
gies. The COLIPA research programme has been designed to devel-
op in vitro assays for several key mechanistic processes involved in
skin sensitisation. Several protocols for the detection of skin sensi-
tising potential of chemicals (hazard) are currently at the pre-
validation stage (i.e., DPRA, h-CLAT and MUSST). However, the
generation of in vitro data that can be translated into quantiﬁable
potency information for practical risk assessment remains a key
challenge.
Equally important is the optimisation of physico-chemical prop-
erty-based prediction models (including in silico tools) and to
explore how the prediction from these models can be appropriately
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ment strategies. To achieve this goal, more chemicals need to be
evaluated within the different available prediction models in order
to investigate their predictivity. Similarly, threshold concepts are
likely to be reﬁned when more data from different chemical classes
are integrated, including the consideration of data from in vitro and
in silico methods to reﬁne for the absence or presence of alerts.
While data gaps and research needs are still to be worked on, a
conceptual approach for the integration of data from various
sources has been outlined. These guiding principles suggesting
how to apply and combine the available tools in a WoE approach
are considered a pragmatic starting point in order to instruct fur-
ther research towards the non-animal quantitative risk assessment
of skin sensitisation. In addition to perspectives provided in recent
reviews (Basketter and Kimber, 2009, 2010; Vandebriel and van
Loveren, 2010), this approach highlights that identiﬁcation of the
relevant mechanistic steps and the optimum set of tools suited
to reliably predict the skin sensitisation potency is a decisive future
need.Conﬂict of interest statement
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